Jacobs Receives Contract to Expand Biopharma Facility in Ireland

PASADENA, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Jacobs Engineering Group Inc. (NYSE: JEC) announced today that it received a contract to provide engineering, procurement, and construction management services to support the ongoing expansion of Genzyme's biopharma fill/finish tabletting facility in Waterford, Ireland.

Officials did not disclose the contract value, yet noted construction is scheduled to be completed in 2009.

Jacobs designed and installed the original Waterford production facility in 2001 which was part of Genzyme's global manufacturing expansion strategy. For the current project, Jacobs will fit out an existing shell and add a new utilities building to expand the 3,600-square-meter facility. The work will be executed from its Dublin office.

Genzyme, headquartered in Cambridge, Massachusetts, is one of the world's leading biotechnology firms. The project is part of recently announced expansion plans that will enable the company to satisfy global demand for its therapeutic products.

Genzyme Ireland's Vice President and General Manager Dominic Carolan said, "The expansion of our Waterford facility will see a very significant increase in the site's biological fill/finish capacity."

In making the announcement, Jacobs Group Vice President Allyn Taylor stated, "We are proud to continue to support Genzyme's global leadership and its role as a major employer in Waterford County."

Jacobs, with over 57,000 employees and revenues exceeding $10.0 billion, provides technical, professional, and construction services globally.

Any statements made in this release that are not based on historical fact are forward-looking statements. Although such statements are based on management's current estimates and expectations, and currently available competitive, financial, and economic data, forward-looking statements are inherently uncertain. We, therefore, caution the reader that there are a variety of factors that could cause business conditions and results to differ materially from what is contained in our forward-looking statements. For a description of some of the factors which may occur that could cause actual results to differ from our forward-looking statements please refer to our 2007 Form 10-K, and in particular the discussions contained under Items 1 - Business, 1A - Risk Factors, 3 - Legal Proceedings, and 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations. We also caution the readers of this release that we do not undertake to update any forward-looking statements made herein.

For additional information contact:

Michelle Jones

626.578.6968

SOURCE Jacobs Engineering Group Inc.



Web site: http://www.jacobs.com